Palbociclib, a drug recently approved by the FDA to treat advanced breast cancer, may have potential for a for a type of thyroid cancer known as papillary thyroid carcinoma. This form of cancer commonly develops a resistance to treatment, in particular the medication vemurafenib. Oncotarget researchers have discovered that by combining the 2 medications they were able to slow cell division that was previously undeterred by vemurafenib alone. Previous research had indicated that in vemuafenib reisitant cells, modification of a certain gene slowed down the division of these cells, palbociclib may have the potential to emulate this process giving hope for those who have developed a resistance to the current PTC treatments on the market. Check the journal at SCImago Journal & Country Rank.
Cancer research encompasses many fields and many discoveries meant to treat certain forms of cancer end up showing potential for treatment relevant to other forms. Oncotarget’s research extends across the board to a plethora of different cancer topics. This dedication to cures and treatments was apparent at 2017’s Frontiers in Cancer Science where Oncotarget awarded 4 different international researchers located in India and Italy. The topics of the winners’ presentations ranged from kidney cancer to Mesothelioma with focus on processes that could contribute to the advancement of many types of cancer treatments. Download output styles at Endnote.com
The success of Oncotarget has prompted us to launch sections beyond oncology – https://t.co/ccRO4O68Oj
— Oncotarget (@OncotargetJrnl) December 14, 2017
2017’s Frontiers in Cancer Research was hosted by 7 internationally known research institutions in Singapore from November 6-8th. “The Frontiers in Cancer Science meeting brings together top cancer experts from around the globe,” states Oncotarget editor-in-chief, Mikhail Blagosklonny. Through travel sponsorships and research grants, Oncotarget’s devotion to ensuring the spread of knowledge in the field of caner research is greatly assisted by participation in events such as FCS help assure that one day there will be hope for anyone with a positive diagnosis of cancer.